RULE_ID|RULE_NAME|MEASURE_TYPE|MODEL|VIEW_NAME|ATTRIBUTE_NAME|DATA_TYPE|PROFILE_TYPE|MIN_VAL|MAX_VAL|CRITICAL|COMMENTS||||
1|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DURATION_IN_DAYS|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
2|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DURATION_IN_DAYS|NUMBER|MAX OF COLUMN|-10|10|N|||||
3|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DURATION_IN_DAYS|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
4|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DURATION_IN_DAYS|NUMBER|MIN OF COLUMN|-10|10|N|||||
5|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DURATION_IN_DAYS|NUMBER|NULL COUNT|-10|10|N|||||
6|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_ADVERSE_EVENT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
7|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_ADVERSE_EVENT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
8|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
9|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
10|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
11|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
12|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
13|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
14|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|HM_SITE_VISIT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
15|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|HM_SITE_VISIT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
16|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
17|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
18|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|HM_ISSUE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
19|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|HM_ISSUE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
20|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_REPORT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
21|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_REPORT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
22|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|HM_QUESTION_ID|NUMBER|NULL COUNT      |-10|10|N|||||
23|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|HM_QUESTION_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
24|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|HM_QUESTION_ID|NUMBER|NULL COUNT      |-10|10|N|||||
25|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|HM_QUESTION_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
26|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|OVERSIGHT_REPORT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
27|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|OVERSIGHT_REPORT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
28|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
29|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
30|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
31|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
32|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
33|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
34|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
35|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
36|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
37|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
38|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
39|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
40|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|HM_SITE_VISIT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
41|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|HM_SITE_VISIT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
42|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
43|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
44|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_PROTOCOL_DEVIATION_ID|NUMBER|NULL COUNT      |-10|10|N|||||
45|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_PROTOCOL_DEVIATION_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
46|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-83|83|N|||||
47|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
48|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
49|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
50|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
51|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
52|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
53|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
54|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
55|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
56|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
57|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
58|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_SITE_PERSONNEL_TURNOVER_ID|NUMBER|NULL COUNT      |-10|10|N|||||
59|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_SITE_PERSONNEL_TURNOVER_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
60|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
61|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
62|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_PERSON_ID|NUMBER|NULL COUNT      |-10|10|N|||||
63|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|HM_PERSON_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
64|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
65|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD|NUMBER|MAX OF COLUMN|-10|10|N|||||
66|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
67|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD|NUMBER|MIN OF COLUMN|-10|10|N|||||
68|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD|NUMBER|NULL COUNT|-10|10|N|||||
69|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_SAE_CASE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
70|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_SAE_CASE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
71|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
72|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
73|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
74|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
75|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
76|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
77|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
78|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
79|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
80|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
81|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
82|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|COMPLIANT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
83|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|COMPLIANT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
84|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|COMPLIANT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
85|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|COMPLIANT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
86|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|COMPLIANT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
87|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_CMPLY_PERCENTAGE|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
88|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_CMPLY_PERCENTAGE|NUMBER|MAX OF COLUMN|-10|10|N|||||
89|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_CMPLY_PERCENTAGE|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
90|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_CMPLY_PERCENTAGE|NUMBER|MIN OF COLUMN|-10|10|N|||||
91|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|VISIT_CMPLY_PERCENTAGE|NUMBER|NULL COUNT|-10|10|N|||||
92|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_CRF_DATA_ENTRY_CMPLY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
93|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_CRF_DATA_ENTRY_CMPLY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
94|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
95|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
96|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
97|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
98|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|MONTH_ID|NUMBER|NULL COUNT      |-10|10|N|||||
99|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|MONTH_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
100|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
101|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MAX OF COLUMN|-10|10|N|||||
102|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
103|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MIN OF COLUMN|-10|10|N|||||
104|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|NULL COUNT|-10|10|N|||||
105|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
106|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
107|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
108|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
109|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
110|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
111|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
112|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
113|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MAX OF COLUMN|-10|10|N|||||
114|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
115|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MIN OF COLUMN|-10|10|N|||||
116|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|NULL COUNT|-10|10|N|||||
117|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
118|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
119|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
120|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
121|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
122|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
123|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
124|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
125|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
126|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
127|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
128|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
129|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
130|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MAX OF COLUMN|-10|10|N|||||
131|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
132|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MIN OF COLUMN|-10|10|N|||||
133|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|NULL COUNT|-10|10|N|||||
134|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
135|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
136|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
137|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MAX OF COLUMN|-10|10|N|||||
138|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
139|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MIN OF COLUMN|-10|10|N|||||
140|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|NULL COUNT|-10|10|N|||||
141|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
142|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
143|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
144|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
145|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
146|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
147|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
148|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
149|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MAX OF COLUMN|-10|10|N|||||
150|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
151|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|MIN OF COLUMN|-10|10|N|||||
152|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TOT_SUBJ_ENTERED_STUDY|NUMBER|NULL COUNT|-10|10|N|||||
153|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
154|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
155|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
156|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
157|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
158|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
159|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
160|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
161|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
162|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
163|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
164|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
165|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
166|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
167|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
168|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
169|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
170|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
171|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
172|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
173|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
174|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
175|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
176|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
177|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
178|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
179|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
180|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
181|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
182|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
183|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
184|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
185|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
186|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
187|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
188|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
189|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
190|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
191|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
192|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
193|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
194|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
195|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
196|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
197|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
198|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
199|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
200|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
201|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
202|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
203|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
204|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
205|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
206|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
207|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
208|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ACTIVE_PATIENT_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
209|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
210|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
211|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
212|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
213|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
214|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|HM_COUNTRY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
215|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
216|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
217|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
218|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
219|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
220|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
221|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
222|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
223|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
224|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
225|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
226|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
227|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
228|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
229|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
230|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
231|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
232|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
233|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
234|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
235|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
236|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
237|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
238|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
239|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
240|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
241|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
242|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
243|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
244|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
245|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
246|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
247|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
248|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
249|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
250|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
251|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
252|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
253|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
254|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
255|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
256|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
257|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
258|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
259|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
260|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
261|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
262|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
263|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
264|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
265|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
266|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
267|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
268|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
269|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
270|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
271|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
272|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
273|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SUBJECT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
274|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SITE_ID|NUMBER|NULL COUNT      |-10|10|N|||||
275|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_SITE_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
276|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_STUDY_ID|NUMBER|NULL COUNT      |-10|10|N|||||
277|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|HM_STUDY_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
278|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
279|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|YN_CUSTOM_QUESTION|CHAR|NULL COUNT|-10|10|N|||||
280|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|INACTIVE|CHAR|NULL COUNT|-10|10|N|||||
281|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|YN_INCONSISTENT_PD|CHAR|NULL COUNT|-10|10|N|||||
282|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
283|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_STUDY_CLOSED|CHAR|NULL COUNT|-10|10|N|||||
284|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
285|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_VISUALIZE|CHAR|NULL COUNT|-10|10|N|||||
286|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
287|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
288|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
289|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
290|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_STUDY_CLOSED|CHAR|NULL COUNT|-10|10|N|||||
291|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
292|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_VISUALIZE|CHAR|NULL COUNT|-10|10|N|||||
293|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
294|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
295|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
296|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
297|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
298|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_VISUALIZE|CHAR|NULL COUNT|-10|10|N|||||
299|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
300|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
301|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
302|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
303|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|YN_STUDY_CLOSED|CHAR|NULL COUNT|-10|10|N|||||
304|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_STUDY_CLOSED|CHAR|NULL COUNT|-10|10|N|||||
305|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
306|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_VISUALIZE|CHAR|NULL COUNT|-10|10|N|||||
307|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
308|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
309|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
310|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
311|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
312|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_VISUALIZE|CHAR|NULL COUNT|-10|10|N|||||
313|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
314|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
315|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
316|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
317|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|YN_STUDY_CLOSED|CHAR|NULL COUNT|-10|10|N|||||
318|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
319|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
320|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
321|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
322|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
323|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
324|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
325|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
326|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
327|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
328|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
329|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
330|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
331|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
332|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
333|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
334|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
335|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
336|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
337|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
338|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|YN_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
339|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|YN_PD_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
340|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|YN_SAE_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
341|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|YN_RT_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
342|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|YN_TL_EXCLUDED|CHAR|NULL COUNT|-10|10|N|||||
343|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|NA|NA|RECORD COUNT|-10|10|N|||||
344|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|NA|NA|RECORD COUNT|-10|10|N|||||
345|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|NA|NA|RECORD COUNT|-10|10|N|||||
346|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|NA|NA|RECORD COUNT|-10|10|N|||||
347|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|NA|NA|RECORD COUNT|-10|10|N|||||
348|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|NA|NA|RECORD COUNT|-10|10|N|||||
349|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|NA|NA|RECORD COUNT|-10|10|N|||||
350|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|NA|NA|RECORD COUNT|-10|10|N|||||
351|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|NA|NA|RECORD COUNT|-10|10|N|||||
352|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|NA|NA|RECORD COUNT|-10|10|N|||||
353|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|NA|NA|RECORD COUNT|-10|10|N|||||
354|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CRF_DATA_ENTRY_COMPL|NA|NA|RECORD COUNT|-10|10|N|||||
355|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|NA|NA|RECORD COUNT|-10|10|N|||||
356|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|NA|NA|RECORD COUNT|-10|10|N|||||
357|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|NA|NA|RECORD COUNT|-10|10|N|||||
358|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|NA|NA|RECORD COUNT|-10|10|N|||||
359|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|NA|NA|RECORD COUNT|-10|10|N|||||
360|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|NA|NA|RECORD COUNT|-10|10|N|||||
361|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|NA|NA|RECORD COUNT|-10|10|N|||||
362|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|NA|NA|RECORD COUNT|-10|10|N|||||
363|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|NA|NA|RECORD COUNT|-10|10|N|||||
364|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|NA|NA|RECORD COUNT|-10|10|N|||||
365|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|NA|NA|RECORD COUNT|-10|10|N|||||
366|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|NA|NA|RECORD COUNT|-10|10|N|||||
367|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|NA|NA|RECORD COUNT|-10|10|N|||||
368|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|NA|NA|RECORD COUNT|-10|10|N|||||
369|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|NA|NA|RECORD COUNT|-10|10|N|||||
370|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|NA|NA|RECORD COUNT|-10|10|N|||||
371|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|NA|NA|RECORD COUNT|-10|10|N|||||
372|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|NA|NA|RECORD COUNT|-10|10|N|||||
373|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|NA|NA|RECORD COUNT|-10|10|N|||||
374|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
375|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|VISIT_REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
376|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|SRC_SYS_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
377|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|RISK_CATEGORY|VARCHAR2|NULL COUNT|-10|10|N|||||
378|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|QUESTION|VARCHAR2|NULL COUNT|-10|10|N|||||
379|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|ANSWER|VARCHAR2|NULL COUNT|-10|10|N|||||
380|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|CRA_DOCUMENT_ISSUE|VARCHAR2|NULL COUNT|-10|10|N|||||
381|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_QUESTIONS|CRA_MANAGING_ISSUE|VARCHAR2|NULL COUNT|-10|10|N|||||
382|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
383|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_SOURCE|VARCHAR2|NULL COUNT|-10|10|N|||||
384|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_MONITORING_ORG|VARCHAR2|NULL COUNT|-10|10|N|||||
385|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
386|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_STATUS_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
387|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|VISIT_REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
388|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|SRC_SYS_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
389|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_SOURCE|VARCHAR2|NULL COUNT|-10|10|N|||||
390|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
391|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|CONTACT_ROLE|VARCHAR2|NULL COUNT|-10|10|N|||||
392|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|CONTACT_ROLE_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
393|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|CONTACT_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
394|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
395|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|INIT_SUPPLIER_SAFETY|VARCHAR2|NULL COUNT|-10|10|N|||||
396|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
397|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|CASE_SERIOUSNESS_CO_CD|VARCHAR2|NULL COUNT|-10|10|N|||||
398|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|CASE_SERIOUSNESS_CO_CD_DESC|VARCHAR2|NULL COUNT|-10|10|N|||||
399|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|CASE_SERIOUSNESS_CRITERIA|VARCHAR2|NULL COUNT|-10|10|N|||||
400|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|E2B_REPORT_TYPE_CD_DESC|VARCHAR2|NULL COUNT|-10|10|N|||||
401|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|MAX_MVI|VARCHAR2|NULL COUNT|-10|10|N|||||
402|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
403|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
404|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
405|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
406|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|CCS_CLINICAL_PLACEMENT|VARCHAR2|NULL COUNT|-10|10|N|||||
407|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
408|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
409|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
410|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
411|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
412|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
413|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
414|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
415|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
416|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
417|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|CCS_CLINICAL_PLACEMENT|VARCHAR2|NULL COUNT|-10|10|N|||||
418|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
419|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
420|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
421|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
422|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
423|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
424|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
425|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
426|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
427|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
428|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
429|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
430|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
431|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
432|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
433|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
434|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|CCS_CLINICAL_PLACEMENT|VARCHAR2|NULL COUNT|-10|10|N|||||
435|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
436|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
437|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
438|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
439|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|CCS_CLINICAL_PLACEMENT|VARCHAR2|NULL COUNT|-10|10|N|||||
440|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
441|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
442|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
443|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
444|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
445|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
446|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
447|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
448|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
449|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
450|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
451|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
452|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
453|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
454|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
455|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
456|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|CCS_CLINICAL_PLACEMENT|VARCHAR2|NULL COUNT|-10|10|N|||||
457|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
458|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
459|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
460|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
461|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
462|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
463|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
464|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
465|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
466|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
467|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
468|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
469|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
470|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
471|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
472|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
473|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
474|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
475|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
476|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
477|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
478|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
479|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
480|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
481|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
482|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
483|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
484|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
485|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
486|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
487|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
488|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
489|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
490|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|NULL COUNT|-10|10|N|||||
491|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
492|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|ETL_COMMENTS|VARCHAR2|NULL COUNT|-10|10|N|||||
493|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|PD_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
494|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SAE_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
495|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|RT_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
496|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|TL_EXCLUDED_REASON|VARCHAR2|NULL COUNT|-10|10|N|||||
497|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
498|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_STATUS_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
499|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
500|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_STATUS_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
501|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
502|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_STATUS_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
503|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY|VARCHAR2|NULL COUNT|-10|10|N|||||
504|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY|VARCHAR2|NULL COUNT|-10|10|N|||||
505|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY|VARCHAR2|NULL COUNT|-10|10|N|||||
506|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_SOURCE|VARCHAR2|NULL COUNT|-10|10|N|||||
507|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
508|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_SOURCE|VARCHAR2|NULL COUNT|-10|10|N|||||
509|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
510|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
511|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_STATUS_DERIVED|VARCHAR2|NULL COUNT|-10|10|N|||||
512|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|N|||||
513|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|N|||||
515|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|N|||||
516|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|N|||||
517|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|N|||||
518|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|N|||||
519|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|N|||||
520|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|N|||||
521|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|N|||||
522|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|N|||||
523|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|N|||||
524|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|N|||||
525|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|N|||||
526|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|N|||||
527|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|N|||||
528|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|N|||||
529|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|N|||||
530|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|N|||||
531|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|N|||||
532|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|N|||||
533|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|N|||||
534|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|N|||||
536|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|N|||||
537|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|N|||||
538|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|N|||||
540|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: EL SALVADOR|0|0|N|||||
541|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|N|||||
542|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|N|||||
543|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|N|||||
544|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|N|||||
545|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|N|||||
547|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|N|||||
548|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|N|||||
549|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|N|||||
550|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|N|||||
551|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|N|||||
552|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|N|||||
553|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|N|||||
554|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|N|||||
555|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|N|||||
556|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|N|||||
557|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|N|||||
558|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|N|||||
559|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|N|||||
560|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|N|||||
561|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|N|||||
563|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|N|||||
564|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|N|||||
565|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|N|||||
566|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|N|||||
567|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDONESIA|0|0|N|||||
568|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|N|||||
570|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|N|||||
571|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|N|||||
572|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|N|||||
573|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|N|||||
574|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|N|||||
575|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|N|||||
577|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|N|||||
578|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|N|||||
579|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|N|||||
580|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: VIET NAM|0|0|N|||||
581|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|N|||||
582|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|N|||||
583|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|N|||||
584|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|N|||||
585|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
586|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
587|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
588|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
589|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
590|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
591|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
592|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
593|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
594|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
595|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
597|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
598|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
599|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
600|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
601|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
602|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
603|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
604|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
605|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
606|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
607|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
608|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
609|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
610|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
611|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
612|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
613|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
614|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
615|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
616|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
617|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
618|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
619|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
620|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
621|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
622|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
623|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
624|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
625|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
626|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
627|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
629|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
630|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
631|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
632|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
633|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
634|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
635|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
636|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
637|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
638|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
639|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
640|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
641|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
642|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
643|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
644|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
645|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
646|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
647|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
648|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
649|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
650|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
651|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
652|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
653|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
654|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
655|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
656|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
657|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|Y|||||
658|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|Y|||||
659|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|Y|||||
661|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
662|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|Y|||||
663|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
664|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|Y|||||
665|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
666|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
667|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|Y|||||
668|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|Y|||||
669|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
670|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
671|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
672|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|Y|||||
673|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|Y|||||
674|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|Y|||||
675|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|Y|||||
676|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
677|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|Y|||||
678|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
679|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|Y|||||
680|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|Y|||||
681|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
682|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
683|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
684|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
685|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
686|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
687|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
688|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
689|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
690|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
691|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
693|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
694|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
695|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
696|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
697|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
698|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
699|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
700|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
701|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
702|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
703|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
704|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
705|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
706|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
707|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
708|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
709|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
710|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
711|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
712|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
713|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
714|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
715|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
716|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
717|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
718|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
719|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
720|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
721|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
722|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
723|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
725|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
726|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
727|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
728|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
729|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
730|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
731|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
732|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
733|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
734|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
735|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
736|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
737|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
738|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
739|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
740|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
741|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
742|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
743|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
744|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
745|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|N|||||
746|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|N|||||
747|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|N|||||
749|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MACEDONIA|0|0|N|||||
750|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|N|||||
753|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|N|||||
754|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|N|||||
755|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|N|||||
756|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|N|||||
757|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|N|||||
758|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BAHAMAS|0|0|N|||||
760|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|N|||||
762|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|N|||||
763|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: OMAN|0|0|N|||||
764|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|N|||||
765|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|N|||||
767|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|N|||||
768|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|N|||||
770|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|N|||||
771|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|N|||||
772|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|N|||||
773|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALTA|0|0|N|||||
774|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|N|||||
775|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|N|||||
776|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|N|||||
777|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|N|||||
778|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|N|||||
779|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|N|||||
780|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|N|||||
781|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|N|||||
782|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|N|||||
783|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|N|||||
784|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|N|||||
785|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|N|||||
786|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|N|||||
787|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|N|||||
788|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|N|||||
789|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|N|||||
791|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|N|||||
792|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|N|||||
793|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|N|||||
794|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|N|||||
795|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|N|||||
796|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|N|||||
797|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|N|||||
798|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|N|||||
799|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|N|||||
800|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|N|||||
801|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|N|||||
802|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|N|||||
803|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|N|||||
804|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|N|||||
805|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|N|||||
806|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|N|||||
807|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|N|||||
808|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|N|||||
809|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|N|||||
810|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|N|||||
811|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|N|||||
812|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|N|||||
813|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|N|||||
814|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|N|||||
815|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|N|||||
816|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|N|||||
817|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|N|||||
818|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|N|||||
819|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|N|||||
820|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|N|||||
821|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|N|||||
822|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|N|||||
823|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|N|||||
824|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|N|||||
825|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|N|||||
826|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|N|||||
827|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|N|||||
829|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|N|||||
830|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|N|||||
832|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|N|||||
833|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|N|||||
834|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|N|||||
835|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MACEDONIA|0|0|N|||||
836|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|N|||||
837|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|N|||||
838|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BAHAMAS|0|0|N|||||
840|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|N|||||
842|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|N|||||
843|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: OMAN|0|0|N|||||
844|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|N|||||
845|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|N|||||
847|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|N|||||
848|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|N|||||
850|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|N|||||
851|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|N|||||
852|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|N|||||
853|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALTA|0|0|N|||||
854|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|N|||||
855|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|N|||||
856|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|N|||||
857|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|N|||||
858|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|N|||||
859|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|N|||||
860|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|N|||||
861|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|N|||||
862|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|N|||||
863|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|N|||||
864|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|N|||||
865|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|N|||||
866|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|N|||||
867|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|N|||||
868|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|N|||||
869|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|N|||||
871|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|N|||||
873|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|N|||||
874|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|N|||||
875|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|N|||||
876|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|N|||||
877|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|N|||||
878|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|N|||||
879|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|N|||||
880|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|N|||||
881|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|N|||||
882|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|N|||||
883|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|N|||||
884|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|N|||||
885|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|N|||||
886|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|N|||||
887|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|N|||||
888|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|N|||||
889|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|N|||||
890|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|N|||||
891|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|N|||||
892|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|N|||||
893|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|N|||||
894|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|N|||||
895|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|N|||||
896|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|N|||||
897|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|N|||||
898|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|N|||||
899|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|N|||||
900|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|N|||||
901|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|N|||||
902|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|N|||||
903|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|N|||||
904|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|N|||||
905|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|Y|||||
906|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|Y|||||
907|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|Y|||||
909|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|N|||||
910|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|Y|||||
912|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|Y|||||
913|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|Y|||||
914|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|Y|||||
915|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|Y|||||
916|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|Y|||||
917|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|Y|||||
918|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BAHAMAS|0|0|Y|||||
920|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|Y|||||
922|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|Y|||||
923|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: OMAN|0|0|Y|||||
924|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|Y|||||
925|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|Y|||||
927|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|Y|||||
928|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|Y|||||
930|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|Y|||||
931|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|Y|||||
932|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|Y|||||
933|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALTA|0|0|Y|||||
934|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|Y|||||
935|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|Y|||||
936|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|Y|||||
937|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|Y|||||
938|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|Y|||||
939|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|Y|||||
940|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|Y|||||
941|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|Y|||||
942|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|Y|||||
943|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|Y|||||
944|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|Y|||||
945|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|Y|||||
946|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|Y|||||
947|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|Y|||||
948|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|Y|||||
949|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|Y|||||
951|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|Y|||||
952|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|Y|||||
953|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|Y|||||
954|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|Y|||||
955|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|Y|||||
956|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MACEDONIA|0|0|Y|||||
957|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|Y|||||
958|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|Y|||||
959|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|Y|||||
960|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|Y|||||
961|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|Y|||||
962|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|Y|||||
963|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|Y|||||
964|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|Y|||||
965|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|Y|||||
966|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|Y|||||
967|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|Y|||||
968|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|Y|||||
969|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|Y|||||
970|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|Y|||||
971|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|Y|||||
972|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|Y|||||
973|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|Y|||||
974|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|Y|||||
975|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|Y|||||
976|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|Y|||||
977|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|Y|||||
978|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|Y|||||
979|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|Y|||||
980|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|Y|||||
981|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|Y|||||
982|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|Y|||||
983|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|Y|||||
984|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|Y|||||
985|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|N|||||
986|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|N|||||
987|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|N|||||
988|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|N|||||
989|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|N|||||
990|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|N|||||
991|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|N|||||
992|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|N|||||
993|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|N|||||
995|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|N|||||
997|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|N|||||
999|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|N|||||
1000|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|N|||||
1001|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|N|||||
1002|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|N|||||
1003|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|Y|||||
1005|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|N|||||
1006|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|N|||||
1008|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|N|||||
1009|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|N|||||
1010|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|N|||||
1013|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|N|||||
1014|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|N|||||
1015|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|N|||||
1016|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|N|||||
1017|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|N|||||
1018|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|N|||||
1019|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|N|||||
1020|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|N|||||
1021|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|N|||||
1022|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|N|||||
1023|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|N|||||
1024|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|N|||||
1025|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|N|||||
1026|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|N|||||
1027|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|N|||||
1028|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|N|||||
1029|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|N|||||
1030|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|N|||||
1031|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|N|||||
1032|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|N|||||
1034|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|N|||||
1035|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|N|||||
1036|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|Y|||||
1037|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|N|||||
1038|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|N|||||
1039|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|N|||||
1040|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|N|||||
1041|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|N|||||
1042|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|N|||||
1043|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|N|||||
1044|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|N|||||
1045|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|N|||||
1046|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|N|||||
1047|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|N|||||
1048|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|N|||||
1049|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|N|||||
1050|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|N|||||
1051|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|N|||||
1052|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|N|||||
1053|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|N|||||
1054|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|N|||||
1055|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|N|||||
1056|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|Y|||||
1057|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|N|||||
1058|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|N|||||
1059|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|N|||||
1060|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|N|||||
1061|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|N|||||
1062|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|N|||||
1063|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|N|||||
1065|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|Y|||||
1066|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|N|||||
1068|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|Y|||||
1069|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|N|||||
1070|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|N|||||
1071|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MACEDONIA|0|0|Y|||||
1072|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|N|||||
1073|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|N|||||
1074|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BAHAMAS|0|0|N|||||
1076|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|N|||||
1078|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|N|||||
1079|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: OMAN|0|0|N|||||
1080|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|N|||||
1081|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|N|||||
1083|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|N|||||
1084|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|N|||||
1086|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|N|||||
1087|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|N|||||
1088|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|N|||||
1089|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALTA|0|0|N|||||
1090|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|N|||||
1091|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|N|||||
1092|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|N|||||
1093|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|N|||||
1094|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|N|||||
1095|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|N|||||
1096|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|N|||||
1097|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|N|||||
1098|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|N|||||
1099|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|N|||||
1100|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|N|||||
1101|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|N|||||
1102|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|N|||||
1103|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|N|||||
1104|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|N|||||
1105|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|N|||||
1107|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|N|||||
1109|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|N|||||
1110|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|N|||||
1111|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|N|||||
1112|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|Y|||||
1113|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|N|||||
1114|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|N|||||
1115|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|N|||||
1116|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|N|||||
1117|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|N|||||
1118|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|N|||||
1119|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|N|||||
1120|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|N|||||
1121|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|N|||||
1122|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|N|||||
1123|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|N|||||
1124|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|N|||||
1125|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|N|||||
1126|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|N|||||
1127|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|N|||||
1128|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|N|||||
1129|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|N|||||
1130|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|N|||||
1131|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|N|||||
1132|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|N|||||
1133|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|N|||||
1134|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|N|||||
1135|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|N|||||
1136|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|N|||||
1137|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|N|||||
1138|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|N|||||
1139|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|N|||||
1140|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|N|||||
1141|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_COLLECTION_DATE|DATE|NULL COUNT|-15|15|N|||||
1142|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1143|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_COLLECTION_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1144|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_STOP_DATE|DATE|NULL COUNT|-15|15|N|||||
1145|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DATE_SITE_AWARE|DATE|NULL COUNT|-15|15|N|||||
1146|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|RANDOMIZATION_DATE|DATE|NULL COUNT|-15|15|N|||||
1147|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|VISIT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1148|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_ISSUE_IDENTIFIED_DT|DATE|NULL COUNT|-15|15|N|||||
1149|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_ISSUE_TARG_RESOL_DT|DATE|NULL COUNT|-15|15|N|||||
1150|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|ACTUAL_RESOLUTION_DT|DATE|NULL COUNT|-15|15|N|||||
1151|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1152|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|NULL COUNT|-15|15|N|||||
1153|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|NULL COUNT|-15|15|N|||||
1154|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|NULL COUNT|-15|15|N|||||
1155|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|NULL COUNT|-125|125|N|||||
1156|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|NULL COUNT|-70|70|N|||||
1157|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|VISIT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1158|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|DATE_DEVIATION_NOTED|DATE|NULL COUNT|-15|15|N|||||
1159|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1160|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|NULL COUNT|-15|15|N|||||
1161|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|STATUS_DATE|DATE|NULL COUNT|-15|15|N|||||
1162|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|INVESTIGATOR_INIT_AWARE_DATE|DATE|NULL COUNT|-15|15|N|||||
1163|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|INIT_RECV_DATE|DATE|NULL COUNT|-15|15|N|||||
1164|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|NULL COUNT|-15|15|N|||||
1165|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1166|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|NULL COUNT|-15|15|N|||||
1167|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1168|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|NULL COUNT|-15|15|N|||||
1169|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|NULL COUNT|-15|15|N|||||
1170|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|NULL COUNT|-15|15|N|||||
1171|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1172|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|NULL COUNT|-15|15|N|||||
1173|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1174|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|NULL COUNT|-15|15|N|||||
1175|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|NULL COUNT|-15|15|N|||||
1176|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|NULL COUNT|-15|15|N|||||
1177|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1178|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|NULL COUNT|-15|15|N|||||
1179|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|NULL COUNT|-15|15|N|||||
1180|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|NULL COUNT|-15|15|N|||||
1181|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1182|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|NULL COUNT|-15|15|N|||||
1183|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1184|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|NULL COUNT|-15|15|N|||||
1185|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1186|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|NULL COUNT|-15|15|N|||||
1187|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|NULL COUNT|-15|15|N|||||
1188|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|NULL COUNT|-15|15|N|||||
1189|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1190|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|NULL COUNT|-15|15|N|||||
1191|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|NULL COUNT|-15|15|N|||||
1192|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|NULL COUNT|-15|15|N|||||
1193|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|NULL COUNT|-15|15|N|||||
1194|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|NULL COUNT|-15|15|N|||||
1195|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1196|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|NULL COUNT|-15|15|N|||||
1197|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1198|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|NULL COUNT|-15|15|N|||||
1199|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|NULL COUNT|-15|15|N|||||
1200|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1201|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|NULL COUNT|-15|15|N|||||
1202|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1203|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|NULL COUNT|-15|15|N|||||
1204|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|NULL COUNT|-15|15|N|||||
1205|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1206|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|NULL COUNT|-15|15|N|||||
1207|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1208|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|NULL COUNT|-15|15|N|||||
1209|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|NULL COUNT|-15|15|N|||||
1210|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1211|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|NULL COUNT|-15|15|N|||||
1212|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1213|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|NULL COUNT|-15|15|N|||||
1214|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|NULL COUNT|-15|15|N|||||
1215|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1216|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|NULL COUNT|-15|15|N|||||
1217|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|NULL COUNT|-15|15|N|||||
1218|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|NULL COUNT|-15|15|N|||||
1219|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|NULL COUNT|-15|15|N|||||
1220|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|NULL COUNT|-15|15|N|||||
1221|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|NULL COUNT|-125|125|N|||||
1222|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|NULL COUNT|-70|70|N|||||
1223|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|NULL COUNT|-15|15|N|||||
1224|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|NULL COUNT|-15|15|N|||||
1225|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|NULL COUNT|-125|125|N|||||
1226|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|NULL COUNT|-70|70|N|||||
1227|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|NULL COUNT|-15|15|N|||||
1228|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|NULL COUNT|-15|15|N|||||
1229|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|NULL COUNT|-125|125|N|||||
1230|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|NULL COUNT|-70|70|N|||||
1231|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1232|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|NULL COUNT|-15|15|N|||||
1233|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|NULL COUNT|-15|15|N|||||
1234|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|NULL COUNT|-15|15|N|||||
1235|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|NULL COUNT|-15|15|N|||||
1236|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|NULL COUNT|-15|15|N|||||
1237|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|NULL COUNT|-125|125|N|||||
1238|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|NULL COUNT|-70|70|N|||||
1239|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_COLLECTION_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1240|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_START_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1241|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_COLLECTION_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1242|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_STOP_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1243|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|AE_DATE_SITE_AWARE|DATE|RANGE OF COLUMN|-10|10|N|||||
1244|DELTA_CHECK|PERCENT|NA|V_W_AE_IN_ADVERSE_EVENT|RANDOMIZATION_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1245|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|VISIT_START_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1246|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_ISSUE_IDENTIFIED_DT|DATE|RANGE OF COLUMN|-10|10|N|||||
1247|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|OVERSIGHT_ISSUE_TARG_RESOL_DT|DATE|RANGE OF COLUMN|-10|10|N|||||
1248|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OR_ISSUES|ACTUAL_RESOLUTION_DT|DATE|RANGE OF COLUMN|-10|10|N|||||
1249|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1250|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1251|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|RANGE OF COLUMN|-10|10|N|||||
1252|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1253|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1254|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1255|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|VISIT_START_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1256|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_PROTOCOL_DEVIATION|DATE_DEVIATION_NOTED|DATE|RANGE OF COLUMN|-10|10|N|||||
1257|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1258|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1259|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SITE_PERS_TURNOVER|STATUS_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1260|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|INVESTIGATOR_INIT_AWARE_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1261|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|INIT_RECV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1262|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1263|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1264|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|RANGE OF COLUMN|-10|10|N|||||
1265|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1266|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1267|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1268|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1269|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1270|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|RANGE OF COLUMN|-10|10|N|||||
1271|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1272|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1273|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1274|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|RANGE OF COLUMN|-10|10|N|||||
1275|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1276|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1277|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1278|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1279|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1280|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1281|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1282|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|RANGE OF COLUMN|-10|10|N|||||
1283|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1284|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1285|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1286|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SUBJECTS|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1287|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1288|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|EARLIEST_FSFV_FROM_MILESTONES|DATE|RANGE OF COLUMN|-10|10|N|||||
1289|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|LATEST_LSLV_FROM_SITES|DATE|RANGE OF COLUMN|-10|10|N|||||
1290|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|PLANNED_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1291|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|ACTUAL_LSLV|DATE|RANGE OF COLUMN|-10|10|N|||||
1292|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1293|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1294|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1295|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1296|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1297|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1298|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1299|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1300|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1301|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1302|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1303|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1304|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1305|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1306|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1307|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1308|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1309|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1310|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1311|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1312|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1313|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_FSFV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1314|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1315|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|SITE_LSLV_DATE_DERIVED|DATE|RANGE OF COLUMN|-10|10|N|||||
1316|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|LAST_MVR_DATE|DATE|RANGE OF COLUMN|-10|10|N|||||
1317|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|RANGE OF COLUMN|-10|10|N|||||
1318|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1319|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1320|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1321|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1322|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1323|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1324|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1325|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1326|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1327|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1328|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1329|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|RANGE OF COLUMN|-38|38|N|||||
1330|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|RANGE OF COLUMN|-38|38|N|||||
1331|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_START_DATE|DATE|RANGE OF COLUMN|-38|38|N|||||
1332|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_OVERSIGHT_REPORTS|REPORT_END_DATE|DATE|RANGE OF COLUMN|-38|38|N|||||
1333|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_COMPLETED_STUDY_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1334|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_DISCONTINUED_DT|DATE|RANGE OF COLUMN|-38|38|N|||||
1335|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1336|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_SUBJECT|SUBJ_ENROLLED_STUDY_DT_DERIVED|DATE|RANGE OF COLUMN|-1142|1142|N|||||
1337|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
1338|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
1339|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
1340|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1341|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
1342|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_MONITORING_VISIT|VISIT_REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1343|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
1344|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
1345|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
1346|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1347|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
1348|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_SITE_VISIT|VISIT_REPORT_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1349|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
1350|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
1351|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
1352|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1353|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
1354|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
1355|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
1356|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
1357|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1358|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|SITE_STATUS|VARCHAR2|NULL COUNT|-10|10|N|||||
1359|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|NULL COUNT|-10|10|N|||||
1360|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|NULL COUNT|-10|10|N|||||
1361|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|NULL COUNT|-10|10|N|||||
1362|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_TYPE|VARCHAR2|NULL COUNT|-10|10|N|||||
1363|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
1364|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
1365|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
1366|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
1367|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
1368|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
1369|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
1370|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
1371|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
1372|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
1373|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
1374|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
1376|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
1377|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
1378|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
1379|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
1380|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
1381|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
1382|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
1383|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
1384|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
1385|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
1386|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
1387|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
1388|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
1389|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
1390|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
1391|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
1392|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
1393|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
1394|ABSOLUTE_CHECK|VALUE|NA|V_W_MI_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
1395|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
1396|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
1397|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
1398|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
1399|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
1400|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
1401|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
1402|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
1403|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
1404|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
1405|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
1406|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
1408|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
1409|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
1410|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
1411|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
1412|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
1413|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
1414|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
1415|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
1416|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
1417|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
1418|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
1419|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
1420|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
1421|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
1422|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
1423|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
1424|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
1425|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
1426|ABSOLUTE_CHECK|VALUE|NA|V_W_PD_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
1427|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1428|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1429|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1430|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1431|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
1432|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
1433|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
1434|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
1435|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|Y|||||
1436|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|Y|||||
1437|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|Y|||||
1438|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
1440|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
1441|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|Y|||||
1442|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|Y|||||
1443|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|Y|||||
1444|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
1445|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
1446|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
1447|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
1448|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|Y|||||
1449|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
1450|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|Y|||||
1451|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
1452|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|Y|||||
1453|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|Y|||||
1454|ABSOLUTE_CHECK|VALUE|NA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
1455|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|Y|||||
1456|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|Y|||||
1457|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|Y|||||
1458|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|Y|||||
1459|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
1460|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
1461|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
1462|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
1463|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
1464|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
1465|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
1466|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
1467|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
1468|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
1469|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
1470|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
1472|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
1473|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
1474|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
1475|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
1476|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
1477|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
1478|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
1479|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
1480|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||
1481|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||
1482|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||
1483|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
1484|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
1485|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
1486|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
1487|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
1488|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
1489|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
1490|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
1491|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|N|||||
1492|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|N|||||
1493|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|N|||||
1494|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|N|||||
1495|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: TERMINATED|0|0|N|||||
1496|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: ONGOING|0|0|N|||||
1497|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_STATUS_CURRENT|VARCHAR2|COUNT OF: COMPLETED|0|0|N|||||
1498|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: IMMUNOLOGY|0|0|N|||||
1499|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|N|||||
1500|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|N|||||
1501|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|N|||||
1502|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: OPHTHALMOLOGY|0|0|N|||||
1504|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: WOMENS HEALTH|0|0|N|||||
1505|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|N|||||
1506|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|N|||||
1507|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|N|||||
1508|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TRANSPLANT|0|0|N|||||
1509|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ALLERGY|0|0|N|||||
1510|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ORAL CARE|0|0|N|||||
1511|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: DERMATOLOGY|0|0|N|||||
1512|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|N|||||1
1513|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: TISSUE REPAIR|0|0|N|||||2
1514|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|N|||||3
1515|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (UROLOGY)|0|0|N|||||
1516|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|N|||||
1517|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|N|||||
1518|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GENITOURINARY (SEXUAL HEALTH)|0|0|N|||||
1519|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|N|||||
1520|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|N|||||
1521|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|N|||||
1522|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|N|||||
1523|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|AVERAGE OF COLUMN|-10|10|N|||||
1524|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MAX OF COLUMN|-10|10|N|||||
1525|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MEDIAN OF COLUMN|-10|10|N|||||
1526|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|MIN OF COLUMN|-10|10|N|||||
1527|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|RISK_CATEGORY_COUNT|NUMBER|NULL COUNT|-10|10|N|||||
1528|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|NULL COUNT      |-10|10|N|||||
1529|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OR_RISK_CAT_COUNT_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
1530|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|NULL COUNT      |-10|10|N|||||
1531|DELTA_CHECK|PERCENT|NA|V_W_RT_IN_OR_RISK_CAT_COUNTS|HM_GL_IN_OVERSIGHT_REPORTS_ID|NUMBER|UNIQUE KEY COUNT|-10|10|N|||||
1532|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|N|||||
1533|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|N|||||
1534|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|N|||||
1535|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|N|||||
1536|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|N|||||
1537|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|N|||||
1538|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|N|||||
1539|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|N|||||
1540|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|N|||||
1541|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|N|||||
1542|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|Y|||||
1543|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|N|||||
1544|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|N|||||
1545|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|N|||||
1546|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|N|||||
1547|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|N|||||
1548|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|N|||||
1549|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|N|||||
1550|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|N|||||
1551|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|N|||||
1552|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|N|||||
1553|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|N|||||
1554|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: EL SALVADOR|-50|50|N|||||
1555|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|N|||||
1556|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|N|||||
1557|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|N|||||
1558|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|N|||||
1559|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|N|||||
1560|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|N|||||
1561|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|N|||||
1562|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|N|||||
1563|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|N|||||
1564|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|N|||||
1565|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|N|||||
1566|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|N|||||
1567|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|N|||||
1568|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|N|||||
1569|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|N|||||
1570|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|N|||||
1571|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|N|||||
1572|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|N|||||
1573|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|N|||||
1574|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|N|||||
1575|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|N|||||
1576|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDONESIA|-50|50|N|||||
1577|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|N|||||
1578|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|N|||||
1579|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|N|||||
1580|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|N|||||
1581|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|N|||||
1582|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|N|||||
1583|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|N|||||
1584|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|N|||||
1585|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|N|||||
1586|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: VIET NAM|-50|50|N|||||
1587|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|N|||||
1588|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|N|||||
1589|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|N|||||
1590|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|N|||||
1591|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|N|||||
1592|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|N|||||
1593|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|N|||||
1594|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|N|||||
1595|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|N|||||
1597|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|N|||||
1598|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|N|||||
1599|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|N|||||
1600|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|N|||||
1601|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|N|||||
1602|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|N|||||
1603|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|N|||||
1604|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|N|||||
1605|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|N|||||
1606|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|N|||||
1607|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|N|||||
1608|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|N|||||
1609|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|N|||||
1610|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|N|||||
1611|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|N|||||
1612|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|N|||||
1613|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|N|||||
1614|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|N|||||
1615|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|N|||||
1616|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|N|||||
1617|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|N|||||
1618|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|N|||||
1619|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|N|||||
1620|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|N|||||
1621|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|N|||||
1622|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|N|||||
1623|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|N|||||
1624|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|N|||||
1625|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|N|||||
1626|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|N|||||
1627|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|N|||||
1628|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|N|||||
1629|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|N|||||
1630|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|N|||||
1631|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|N|||||
1632|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|N|||||
1633|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|N|||||
1634|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|N|||||
1635|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|N|||||
1636|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|N|||||
1637|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|N|||||
1638|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|N|||||
1639|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|N|||||
1640|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|N|||||
1641|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|N|||||
1642|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|N|||||
1643|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|N|||||
1644|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|N|||||
1645|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|N|||||
1646|DELTA_CHECK|PERCENT|NA|V_W_MI_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|N|||||
1647|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|N|||||
1648|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|N|||||
1649|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|N|||||
1650|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|N|||||
1651|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|N|||||
1652|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|N|||||
1653|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|N|||||
1654|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|N|||||
1655|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|N|||||
1656|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|N|||||
1657|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|N|||||
1658|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|N|||||
1659|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|N|||||
1660|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|N|||||
1661|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|N|||||
1662|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|N|||||
1663|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|N|||||
1664|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|N|||||
1665|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|N|||||
1666|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|N|||||
1667|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|N|||||
1668|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|N|||||
1669|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|N|||||
1670|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|N|||||
1671|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|N|||||
1672|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|N|||||
1673|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|N|||||
1674|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|N|||||
1675|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|N|||||
1676|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|N|||||
1677|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|N|||||
1678|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|N|||||
1679|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|N|||||
1680|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|N|||||
1681|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|N|||||
1682|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|N|||||
1683|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|N|||||
1684|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|N|||||
1685|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|N|||||
1686|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|N|||||
1687|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|N|||||
1688|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|N|||||
1689|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|N|||||
1690|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|N|||||
1691|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|N|||||
1692|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|N|||||
1693|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|N|||||
1694|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|N|||||
1695|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|N|||||
1696|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|N|||||
1697|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|N|||||
1698|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|N|||||
1699|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|N|||||
1700|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|N|||||
1701|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|N|||||
1702|DELTA_CHECK|PERCENT|NA|V_W_PD_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|N|||||
1703|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|Y|||||
1704|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|Y|||||
1705|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|N|||||
1706|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|Y|||||
1707|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|Y|||||
1709|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|Y|||||
1710|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|Y|||||
1711|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|Y|||||
1712|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|Y|||||
1713|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|Y|||||
1714|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|Y|||||
1715|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|Y|||||
1716|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|Y|||||
1717|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|Y|||||
1718|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|Y|||||
1719|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|Y|||||
1720|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|Y|||||
1721|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|Y|||||
1722|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|Y|||||
1723|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|Y|||||
1724|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|Y|||||
1725|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|Y|||||
1726|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|Y|||||
1727|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|Y|||||
1728|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|Y|||||
1729|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|Y|||||
1730|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|Y|||||
1731|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|Y|||||
1732|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|Y|||||
1733|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|Y|||||
1734|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|Y|||||
1735|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|Y|||||
1736|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|Y|||||
1737|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|Y|||||
1738|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|Y|||||
1739|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|Y|||||
1740|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|Y|||||
1741|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|Y|||||
1742|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|Y|||||
1743|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|Y|||||
1744|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|Y|||||
1745|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|Y|||||
1746|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|Y|||||
1747|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|Y|||||
1748|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|Y|||||
1749|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|Y|||||
1750|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|Y|||||
1751|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|Y|||||
1752|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|Y|||||
1753|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|Y|||||
1754|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|Y|||||
1755|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|Y|||||
1756|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|Y|||||
1757|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|Y|||||
1758|DELTA_CHECK|PERCENT|OH|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|Y|||||
1759|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|N|||||
1760|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|N|||||
1761|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|N|||||
1762|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|N|||||
1763|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|N|||||
1764|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|N|||||
1765|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|N|||||
1766|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|N|||||
1767|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|N|||||
1768|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|N|||||
1769|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|N|||||
1770|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|N|||||
1771|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|N|||||
1772|ABSOLUTE_CHECK|VALUE|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|N|||||
1773|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|N|||||
1774|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|N|||||
1775|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|N|||||
1776|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|N|||||
1777|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|N|||||
1778|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|N|||||
1779|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|N|||||
1780|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|N|||||
1781|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|N|||||
1782|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|N|||||
1783|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|N|||||
1784|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|N|||||
1785|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|N|||||
1786|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|N|||||
1787|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|N|||||
1788|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|N|||||
1789|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|N|||||
1790|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|N|||||
1791|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|N|||||
1792|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|N|||||
1793|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|N|||||
1794|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|N|||||
1795|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|N|||||
1796|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|N|||||
1797|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|N|||||
1798|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|N|||||
1799|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|N|||||
1800|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|N|||||
1801|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|N|||||
1802|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|N|||||
1803|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|N|||||
1804|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|N|||||
1805|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|N|||||
1806|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|N|||||
1807|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|N|||||
1808|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|N|||||
1809|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|N|||||
1811|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|N|||||
1812|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|N|||||
1813|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|N|||||
1814|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|N|||||
1815|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|N|||||
1816|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|N|||||
1818|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|N|||||
1819|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|N|||||
1820|DELTA_CHECK|PERCENT|NA|V_W_SAE_IN_SAE_CASE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|N|||||
1821|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|N|||||
1822|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|N|||||
1823|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|N|||||
1824|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|N|||||
1825|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|N|||||
1826|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|N|||||
1827|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|N|||||
1828|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|N|||||
1829|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|N|||||
1830|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|N|||||
1831|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|N|||||
1832|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|N|||||
1833|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|N|||||
1834|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|N|||||
1835|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|N|||||
1836|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|N|||||
1837|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|N|||||
1838|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|N|||||
1839|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|N|||||
1840|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|N|||||
1841|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|N|||||
1842|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|N|||||
1843|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|N|||||
1844|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|N|||||
1845|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|N|||||
1846|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|N|||||
1847|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|N|||||
1848|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|N|||||
1849|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|N|||||
1850|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|N|||||
1851|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|N|||||
1852|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|N|||||
1853|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|N|||||
1854|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|N|||||
1855|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|N|||||
1856|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|N|||||
1857|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|N|||||
1858|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|N|||||
1859|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|N|||||
1860|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|N|||||
1861|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|N|||||
1862|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|N|||||
1863|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|N|||||
1864|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|N|||||
1865|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|N|||||
1866|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|N|||||
1867|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|N|||||
1868|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|N|||||
1869|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|N|||||
1870|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|N|||||
1871|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|Y|||||
1872|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|Y|||||
1873|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|Y|||||
1874|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|Y|||||
1875|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|Y|||||
1876|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|Y|||||
1877|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|Y|||||
1878|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|Y|||||
1879|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|Y|||||
1880|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|Y|||||
1881|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|Y|||||
1882|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|Y|||||
1883|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|Y|||||
1884|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|Y|||||
1885|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFECTIOUS DISEASES|0|0|Y|||||
1886|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: INFLAMMATION|0|0|Y|||||
1887|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (NEUROLOGY)|0|0|Y|||||
1888|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: GASTROINTESTINAL|0|0|Y|||||
1889|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: METABOLIC DISEASE|0|0|Y|||||
1890|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NOT APPLICABLE|0|0|Y|||||
1891|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ENDOCRINE DISEASE|0|0|Y|||||
1892|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: CARDIOVASCULAR|0|0|Y|||||
1893|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: HEMATOLOGY|0|0|Y|||||
1894|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: NEUROSCIENCE (PSYCHIATRY)|0|0|Y|||||
1895|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: ONCOLOGY|0|0|Y|||||
1896|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: PAIN|0|0|Y|||||
1897|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: RESPIRATORY|0|0|Y|||||
1898|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|STUDY_THERAPEUTIC_AREA|VARCHAR2|COUNT OF: VACCINES|0|0|Y|||||
1899|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1900|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1901|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1902|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1903|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1904|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1905|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1906|ABSOLUTE_CHECK|VALUE|TL|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1907|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1908|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1909|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1910|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1911|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1912|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1913|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1914|ABSOLUTE_CHECK|VALUE|TO|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1915|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1916|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1917|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1918|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1919|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE IV|0|0|Y|||||
1920|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE I|0|0|Y|||||
1921|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE II|0|0|Y|||||
1922|ABSOLUTE_CHECK|VALUE|OH|V_W_RT_IN_CLINICAL_STUDY|DEVELOPMENT_PHASE|VARCHAR2|COUNT OF: PHASE III|0|0|Y|||||
1923|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|0|0|Y|||||
1924|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GAMBIA|0|0|Y|||||
1925|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|0|0|Y|||||
1927|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|0|0|N|||||
1928|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|0|0|Y|||||
1930|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOLDOVA|0|0|N|||||
1931|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|0|0|Y|||||
1932|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PANAMA|0|0|Y|||||
1933|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|0|0|N|||||
1934|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|0|0|Y|||||
1935|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|0|0|Y|||||
1936|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BAHAMAS|0|0|Y|||||
1938|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|0|0|Y|||||
1940|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|0|0|Y|||||
1941|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: OMAN|0|0|Y|||||
1942|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|0|0|Y|||||
1943|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|0|0|Y|||||
1945|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|0|0|Y|||||
1946|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELARUS|0|0|Y|||||
1948|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|0|0|Y|||||
1949|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|0|0|Y|||||
1950|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|0|0|Y|||||
1951|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALTA|0|0|Y|||||
1952|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|0|0|Y|||||
1953|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|0|0|Y|||||
1954|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|0|0|Y|||||
1955|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|0|0|Y|||||
1956|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|0|0|Y|||||
1957|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|0|0|Y|||||
1958|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|0|0|Y|||||
1959|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LUXEMBOURG|0|0|Y|||||
1960|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MOROCCO|0|0|Y|||||
1961|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|0|0|Y|||||
1962|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED ARAB EMIRATES|0|0|Y|||||
1963|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|0|0|Y|||||
1964|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|0|0|Y|||||
1965|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|0|0|Y|||||
1966|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|0|0|Y|||||
1967|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|0|0|Y|||||
1969|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|0|0|Y|||||
1970|ABSOLUTE_CHECK|VALUE|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MACEDONIA|0|0|N|||||
1971|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|0|0|Y|||||
1972|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|0|0|Y|||||
1973|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|0|0|Y|||||
1975|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TUNISIA|0|0|Y|||||
1976|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|0|0|Y|||||
1977|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|0|0|Y|||||
1978|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|0|0|Y|||||
1979|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|0|0|Y|||||
1980|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|0|0|Y|||||
1981|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|0|0|Y|||||
1982|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: QATAR|0|0|Y|||||
1983|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|0|0|Y|||||
1984|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVENIA|0|0|Y|||||
1985|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|0|0|Y|||||
1986|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|0|0|Y|||||
1987|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|0|0|Y|||||
1988|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JORDAN|0|0|Y|||||
1989|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|0|0|Y|||||
1990|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|0|0|Y|||||
1991|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|0|0|Y|||||
1992|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|0|0|Y|||||
1993|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|0|0|Y|||||
1994|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|0|0|Y|||||
1995|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|0|0|Y|||||
1996|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DOMINICAN REPUBLIC|0|0|Y|||||
1997|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|0|0|Y|||||
1998|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|0|0|Y|||||
1999|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|0|0|Y|||||
2000|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|0|0|Y|||||
2001|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|0|0|Y|||||
2002|ABSOLUTE_CHECK|VALUE|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|0|0|Y|||||
2003|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRALIA|-50|50|Y|||||
2004|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GERMANY|-50|50|Y|||||
2005|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: KOREA|-50|50|N|||||
2006|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LATVIA|-50|50|Y|||||
2007|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NORWAY|-50|50|Y|||||
2008|DELTA_CHECK|PERCENT|NA|V_W_TL_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TAIWAN|-50|50|N|||||
2009|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED STATES|-50|50|Y|||||
2010|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ARGENTINA|-50|50|Y|||||
2011|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ESTONIA|-50|50|Y|||||
2012|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NEW ZEALAND|-50|50|Y|||||
2013|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ROMANIA|-50|50|Y|||||
2014|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: RUSSIAN FEDERATION|-50|50|Y|||||
2015|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: AUSTRIA|-50|50|Y|||||
2016|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COSTA RICA|-50|50|Y|||||
2017|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FRANCE|-50|50|Y|||||
2018|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HONG KONG|-50|50|Y|||||
2019|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MEXICO|-50|50|Y|||||
2020|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: NETHERLANDS|-50|50|Y|||||
2021|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BELGIUM|-50|50|Y|||||
2022|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BRAZIL|-50|50|Y|||||
2023|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CROATIA|-50|50|Y|||||
2024|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: DENMARK|-50|50|Y|||||
2025|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: INDIA|-50|50|Y|||||
2026|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PHILIPPINES|-50|50|Y|||||
2027|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BOSNIA AND HERZEGOVINA|-50|50|Y|||||
2028|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: BULGARIA|-50|50|Y|||||
2029|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHINA|-50|50|Y|||||
2030|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: FINLAND|-50|50|Y|||||
2031|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ITALY|-50|50|Y|||||
2032|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: LITHUANIA|-50|50|Y|||||
2033|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: MALAYSIA|-50|50|Y|||||
2034|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SINGAPORE|-50|50|Y|||||
2035|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SPAIN|-50|50|Y|||||
2036|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CANADA|-50|50|Y|||||
2037|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: COLOMBIA|-50|50|Y|||||
2038|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GEORGIA|-50|50|Y|||||
2039|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: HUNGARY|-50|50|Y|||||
2040|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PERU|-50|50|Y|||||
2041|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: POLAND|-50|50|Y|||||
2042|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SLOVAKIA|-50|50|Y|||||
2043|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWEDEN|-50|50|Y|||||
2044|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: TURKEY|-50|50|Y|||||
2045|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: IRELAND|-50|50|Y|||||
2046|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PORTUGAL|-50|50|Y|||||
2047|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: PUERTO RICO|-50|50|Y|||||
2048|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SERBIA|-50|50|Y|||||
2049|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: THAILAND|-50|50|Y|||||
2050|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UKRAINE|-50|50|Y|||||
2051|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CHILE|-50|50|Y|||||
2052|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: CZECH REPUBLIC|-50|50|Y|||||
2053|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: GREECE|-50|50|Y|||||
2054|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: ISRAEL|-50|50|Y|||||
2055|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: JAPAN|-50|50|Y|||||
2056|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SOUTH AFRICA|-50|50|Y|||||
2057|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: SWITZERLAND|-50|50|Y|||||
2058|DELTA_CHECK|PERCENT|SA|V_W_RT_IN_CLINICAL_STUDY_SITE|COUNTRY_NAME|VARCHAR2|COUNT OF: UNITED KINGDOM|-50|50|Y|||||
